Drug-eluting bead transarterial chemoembolization as neoadjuvant therapy pre-liver transplantation for advanced-stage hepatocellular carcinoma

doi:10.4251/wjgo.v16.i6.2476

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (480)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

HTML

332

Figures (1-5)

Tables (1-4)

Sum=429

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=41

Jun 15, 2024 (publication date) through Jul 11, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2476-2486
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2476

Table 4 Univariate and multivariate Cox proportional hazards model for recurrence-free survival and overall survival

Variable	Univariate analysis				Multivariate analysis
Variable	Total, n	HR	95%CI	P value	HR	95%CI	P value
RFS
Pre-LT DEB-TACE as yes/no	45/54	2.62	1.41-4.89	0.002	2.73	1.44-5.14	0.002
Child-Pugh classification
A	83	Reference	N/A	N/A	N/A	N/A	N/A
B	12	2.03	0.98-4.23	0.056	N/A	N/A	N/A
C	4	1.52	0.36-6.35	0.559	N/A	N/A	N/A
Macrovascular invasion as yes/no	31/68	1.74	0.98-3.09	0.056	N/A	N/A	N/A
Overall diameter of target (tumors in cm for ≤ 7 cm/> 7 cm)	46/53	2.55	1.38-4.69	0.003	1.98	1.05-3.75	0.035
AFP of ≤ 400 ng/mL/> 400 ng/mL)	74/25	2.34	1.30-4.19	0.004	2.27	1.23-4.21	0.009
Tumor differentiation
Well differentiated	3	Reference	N/A	N/A	N/A	N/A	N/A
Moderately differentiated	71	1.42	0.19-10.45	0.726	N/A	N/A	N/A
Undifferentiated	25	2.27	0.30-17.13	0.426	N/A	N/A	N/A
OS
Pre-LT DEB-TACE as yes/no	45/54	3.33	1.51-7.34	0.003	3.15	1.43-6.96	0.004
Child-Pugh classification
A	83	Reference	N/A	N/A	N/A	N/A	N/A
B	12	2.46	1.06-5.68	0.035	N/A	N/A	N/A
C	4	1.81	0.42-7.66	0.41	N/A	N/A	N/A
Macrovascular invasion as yes/no	31/68	1.25	0.62-2.48	0.524	N/A	N/A	N/A
Overall diameter of target (tumors in cm of ≤ 7 cm/> 7 cm)	46/53	2.09	1.02-4.28	0.042	N/A	N/A	N/A
AFP of ≤ 400 ng/mL/> 400 ng/mL	74/25	1.68	0.83-3.39	0.145	N/A	N/A	N/A
Tumor differentiation
Well differentiated	3	Reference	N/A	N/A	N/A	N/A	N/A
Moderately differentiated	71	N/A	NA¹	0.922	N/A	N/A	N/A
Undifferentiated	25	N/A	NA¹	0.920	N/A	N/A	N/A

¹Heart rate calculation and inclusion of the covariate in univariate analysis was not applicable due to the lack of hepatocellular carcinoma deaths in the well-differentiated group.

RFS: Recurrence-free survival; 95%CI: 95% confidence interval; AFP: Alpha-fetoprotein; DEB-TACE: Drug-eluting bead transcatheter arterial chemoembolization; HR: Hazard ratio; LT: Liver transplantation; N/A: Not applicable; OS: Overall survival; NA: Not available.

Citation: Ye ZD, Zhuang L, Song MC, Yang Z, Zhang W, Zhang JF, Cao GH. Drug-eluting bead transarterial chemoembolization as neoadjuvant therapy pre-liver transplantation for advanced-stage hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(6): 2476-2486
URL: https://www.wjgnet.com/1948-5204/full/v16/i6/2476.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i6.2476